skip to main content

Postpartum lipid management after myocardial infarction — ABIM Board MCQ

Instant feedback + full explanation. One question, done properly.

HardHyperlipidemiaPostpartum lipid management after myocardial infarctionABIM Board

A 34-year-old woman is evaluated 2 days after an uncomplicated delivery. At 30 weeks’ gestation, she had an anterior ST-segment elevation myocardial infarction and underwent drug-eluting stent placement. She also has heterozygous familial hypercholesterolemia. Before conception, she took atorvastatin 80 mg daily, which was discontinued when pregnancy was recognized. Her current LDL cholesterol is 238 mg/dL. She is hemodynamically stable and has normal aminotransferase, creatinine, and thyroid-stimulating hormone levels. She plans to exclusively breastfeed for at least 6 months. Which of the following is the most appropriate immediate lipid-management plan?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Resume atorvastatin 80 mg daily and advise formula feeding rather than breastfeeding

This patient requires immediate resumption of high-intensity statin therapy and should not breastfeed. Her recent myocardial infarction establishes clinical ASCVD, and heterozygous familial hypercholesterolemia with an LDL cholesterol of 238 mg/dL further increases her recurrent-event risk. Temporary interruption of therapy during lactation, which may be reasonable for many patients receiving statins solely for primary hypercholesterolemia, is inappropriate after a recent acute coronary event. The FDA removed the blanket pregnancy contraindication for statins but continues to advise against breastfeeding when ongoing statin treatment is required. Infant monitoring does not make statin exposure through human milk acceptable, and using low-intensity pravastatin does not address her secondary-prevention needs. Colesevelam is minimally absorbed and may be considered when lipid treatment is needed during pregnancy or lactation, but it is not an adequate substitute for guideline-directed high-intensity statin therapy after myocardial infarction. Deferring all treatment similarly leaves a very-high-risk patient untreated. Atorvastatin should therefore be resumed now, formula feeding should be recommended, and the lipid response should subsequently be reassessed to determine whether additional nonstatin therapy is required to reach the secondary-prevention LDL-C goal.

Reference: FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins (July 20, 2021) — https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy Top Things to Know: Guideline on the Management of Dyslipidemia (March 13, 2026) — https://professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia/top-things-to-know